Truist Securities analyst Danielle Brill reiterated a Buy rating and $315.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments